Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

January 13th 2025

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.

Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC

January 11th 2025

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

Dr Piotrowska on Treatment Sequencing Decisions in HER2-Mutated NSCLC

January 10th 2025

Zosia Piotrowska, MD, MHS, discusses disease factors that guide treatment decision-making and sequencing for patients with HER2-mutated NSCLC.

First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC

January 9th 2025

Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.

Blinatumomab Becomes Standard Addition to Consolidation Chemo in B-ALL, Irrespective of MRD Status

January 9th 2025

Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management

Phase 3 Study of Ameluz-PDT in Superficial Basal Cell Carcinoma Reaches 1-Year Follow-Up to Support FDA sNDA Submission

January 8th 2025

The phase 3 ALA-BCC-CT013 study of Ameluz and RhodoLED PDT in sBCC had its last enrolled patient complete a 1-year follow-up visit.

Invikafusp Alfa Receives FDA Fast Track Designation for TMB-High CRC

January 8th 2025

Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.

China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

January 8th 2025

Enfortumab vedotin-efjv plus has received NMPA approval for patients with locally advanced or metastatic urothelial cancer.

Dr Borgen on the Use of AI to Support Treatment Decision-Making in Oncology

January 7th 2025

Patrick Borgen, MD, discusses how advances in artificial intelligence may influence the future of oncology practice.

Dr Borgen on the Strengths and Limitations of AI in Oncology Practice

January 7th 2025

Patrick I. Borgen, MD, discusses research outlining the current clinical applications and limitations of artificial intelligence in oncology practice.

Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis

January 7th 2025

Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

January 6th 2025

Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.

ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups

January 6th 2025

Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.

Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

January 6th 2025

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

Tarlatamab Earns UK Approval for Previously Treated ES-SCLC

January 6th 2025

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

Distinctions Between Alteration Types, Therapeutic Classes Could Drive Optimal Treatment Selection in HER2-Mutant NSCLC

January 3rd 2025

Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.

European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC

January 2nd 2025

The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.

FDA Grants Priority Review to Avutometinib Plus Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer

January 2nd 2025

The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

December 23rd 2024

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

December 23rd 2024

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.